Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of…
USD130.95-2.55%vs prev. close
Performance
1W
-0.83%
1M
-3.91%
3M
-15.57%
1Y
+57.32%
YTD
+49.93%
Valuation
P/E
28.4
EPS TTM
4.73
Dividend yield
—
Size and risk
Market cap
$8.5B
Beta
1.22
Price history
PTGX price
USD
Total returnEventsVs index
Loading…
Next earnings
Report date
EPS estimate
Revenue estimate
Peer comparison
Protagonist Therapeutics
PTGX
Biotechnology
Mkt cap (USD bn)
8.5
P/E
28.4
Div yld
—
1W
-0.8%
1M
-3.9%
3M
-15.6%
6M
+28.2%
1Y
+57.3%
YTD
+49.9%
Company
Ticker
Industry
Mkt cap (USD bn)
P/E
Div yld
1W
1M
3M
6M
1Y
YTD
Protagonist Therapeutics
PTGX
Biotechnology
8.5
28.4
—
-0.8%
-3.9%
-15.6%
+28.2%
+57.3%
+49.9%
Subscribe to Equity Analytics to compare PTGX with its closest peers
Sector-matched peer set with side-by-side valuation, dividend and performance over every window.